panbronchiolitis%20-%20diffuse
PANBRONCHIOLITIS - DIFFUSE
Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Panbronchiolitis%20-%20diffuse Treatment

Pharmacotherapy

  • Macrolides should be started as soon as diagnosis is established

Macrolides

  • Eg Erythromycin,14 member-ringed macrolides (eg Clarithromycin, Roxithromycin), & the 15 member-ringed macrolide Azithromycin
  • Erythromycin is the 1st choice in treatment of diffuse panbronchiolitis (DPB)
    • Treatment duration is for at least 6 months
  • Other macrolides (Clarithromycin, Roxithromycin, Azithromycin) are used when Erythromycin is ineffective or not tolerated
  • Studies show better lung function (decreased dyspnea, opacities in HRCT) w/ Azithromycin use in patients w/ DPB

Actions:

  • Inhibit production of pro-inflammatory cytokines & formation of leukotriene B4
  • Block the formation of adhesion molecules required for migration of neutrophils

Effects:

  • Decreased inflammation of the airways, leading to improved pulmonary function & decreased infection
  • Erythromycin helps improve host defense & regulate bacterial activities
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.